Biotech | June 19, 2023
Laurus Labs signs MOA with IIT Kanpur for novel gene therapy assets
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Laurus will also provide funding for the clinical trials and will launch these products in India and emerging markets
Columvi is part of Roche's industry-leading portfolio of T-cell engaging bispecific antibodies in non-Hodgkin lymphoma, which also includes the recently approved Lunsumio to treat follicular lymphoma
Based on a subgroup analysis by PD-L1 expression from KEYNOTE-811, Merck is working with the US FDA to update the current indication for KEYTRUDA in HER2-positive gastric or GEJ adenocarcinoma
Collaboration to accelerate and de-risk clinical development of Nanopharmaceutics CNS portfolio
Economic analysis of cost of Vall d’Hebron University Hospital Stroke Unit shows direct-to-angio stroke pathway can save more than USD 3,000 per patient
Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Pfizer is likely to show GSK significant competition
UTD2 is the world's first oral epothilone microtubule inhibitor
Chinook Therapeutics is a clinical-stage biopharmaceutical company with two high-value, late-stage assets in development for IgA nephropathy (IgAN), a rare, progressive chronic kidney disease
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Subscribe To Our Newsletter & Stay Updated
